ADPT - Adaptive Biotechnologies Corp Stock Price, Fair Value and News

$6.06-0.23 (-3.66%)

Delayed as of 30 Dec 2024, 11:02 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ADPT Price Action

Last 7 days

-1.6%

Last 30 days

9.8%

Last 90 days

25.8%

Trailing 12 Months

18.0%

ADPT RSI Chart

ADPT Valuation

Market Cap

928.3M

Price/Earnings (Trailing)

-4.75

Price/Sales (Trailing)

5.24

Price/Free Cashflow

-8.1

ADPT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ADPT Fundamentals

ADPT Revenue

Revenue (TTM)

177.3M

Rev. Growth (Yr)

22.46%

Rev. Growth (Qtr)

7.51%

ADPT Earnings

Earnings (TTM)

-195.2M

Earnings Growth (Yr)

36.24%

Earnings Growth (Qtr)

30.62%

ADPT Profitability

Return on Equity

-87.25%

Return on Assets

-34.96%

Free Cashflow Yield

-12.34%

ADPT Investor Care

Shares Dilution (1Y)

1.94%

Diluted EPS (TTM)

-1.34

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	174.5M	168.8M	177.3M	0
2023	184.3M	189.6M	179.7M	170.3M
2022	154.5M	159.7M	168.0M	185.3M
2021	115.9M	133.4M	146.6M	154.3M
2020	93.3M	92.2M	92.4M	98.4M
2019	58.6M	69.2M	78.1M	85.1M
2018	0	44.2M	49.9M	55.7M
2017	0	0	0	38.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer and autoimmune disorders. It offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

CEO	Mr. Chad M. Robins M.B.A, M.B.A.
WEBSITE	adaptivebiotech.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	790

Adaptive Biotechnologies Corp Frequently Asked Questions

What is the ticker symbol for Adaptive Biotechnologies Corp? What does ADPT stand for in stocks?

ADPT is the stock ticker symbol of Adaptive Biotechnologies Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adaptive Biotechnologies Corp (ADPT)?

As of Fri Dec 27 2024, market cap of Adaptive Biotechnologies Corp is 928.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADPT stock?

You can check ADPT's fair value in chart for subscribers.

Is Adaptive Biotechnologies Corp a good stock to buy?

The fair value guage provides a quick view whether ADPT is over valued or under valued. Whether Adaptive Biotechnologies Corp is cheap or expensive depends on the assumptions which impact Adaptive Biotechnologies Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADPT.

What is Adaptive Biotechnologies Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 27 2024, ADPT's PE ratio (Price to Earnings) is -4.75 and Price to Sales (PS) ratio is 5.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADPT PE ratio will change depending on the future growth rate expectations of investors.